Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 10/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.39 |
| ▸ | DDX3X | O00571 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12307709 | 0.89 | PHGDH (0.40) | PRMT3PHGDHIMPDH2DDX3XCYP19A1 | |
| SCHEMBL12307596 | 0.87 | MAPK13 (0.38) | PHGDH | |
| SCHEMBL12307566 | 0.84 | GRM5 (0.35) | ABL1MAP4K1 | |
| SCHEMBL12307501 | 0.83 | HDAC1 (0.41) | PHGDH | |
| SCHEMBL12307597 | 0.80 | PLK1 (0.43) | ABL1 | |
| SCHEMBL12307539 | 0.79 | MEN1 (0.42) | — | |
| SCHEMBL12307717 | 0.79 | POLB (0.43) | PRMT3IMPDH2MAP4K1 | |
| SCHEMBL12307527 | 0.79 | ALDH1A1 (0.42) | — | |
| SCHEMBL12307500 | 0.79 | GCK (0.42) | — | |
| SCHEMBL12307398 | 0.79 | GCK (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R5, PIK3R4, PIK3R1 | PRMT3 1580/4885ABL1 327/4885PHGDH 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.